GOP Pushes THC Testing Carve-Out Despite Cannabis Rescheduling Progress

Republican lawmakers are mobilizing to preserve workplace THC testing requirements for safety-sensitive positions even as the Trump administration moves forward with cannabis rescheduling. Representatives Andy Harris (R-MD) and Pete Sessions (R-TX) led a Capitol Hill press conference Thursday demanding specific carve-outs that would maintain current drug testing protocols for transportation workers regardless of any federal scheduling changes.

The push creates a complex regulatory landscape that could limit the practical benefits of rescheduling for cannabis companies and consumers. While rescheduling would remove cannabis from Schedule I status and potentially unlock banking services and tax benefits under 280E, workplace testing restrictions would preserve significant barriers to mainstream adoption. This patchwork approach mirrors the current state-federal divide that has constrained industry growth and institutional investment.

Transportation and logistics represent major employment sectors where cannabis normalization could drive demand growth. Federal contractors, airline personnel, truck drivers, and railroad workers currently face zero-tolerance policies that create a substantial pool of potential consumers currently excluded from legal cannabis markets. Maintaining these restrictions would cap the addressable market even under a more favorable federal framework.

The Republican position reflects broader conservative resistance to cannabis liberalization despite growing bipartisan support for reform. Anti-prohibition groups backing the carve-out proposal understand that workplace restrictions serve as a practical prohibition mechanism even when products are technically legal. This strategy could appeal to moderate Republicans who support medical access while maintaining law enforcement and workplace safety arguments.

Cannabis operators face continued uncertainty as competing political forces shape federal policy. The industry has rallied on rescheduling optimism, but targeted restrictions could limit the financial impact of any regulatory changes. Companies with exposure to B2B markets or safety-sensitive industries must navigate this evolving compliance landscape while investors weigh the potential for partial rather than comprehensive federal reform.